You are here

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma, Glioblastoma, Hepatocellular Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Dose Escalation Population: Histological or cytological diagnosis of
advanced/metastatic solid tumor that is resistant to standard therapy or for which no
standard therapy is available. Lesions may be measurable or non measurable.

- Expansion Population 1: Patients with histologically confirmed metastatic renal cell
cancer with no prior systemic therapy directed at the malignant tumor.

- Expansion Population 2: Patients with histologically confirmed metastatic renal cell
cancer whose prior systemic therapy directed at the malignant tumor was single agent
VEGF inhibitor and who now have acquired resistance to this treatment. Resistance is
defined as progression following an initial response (complete or partial), or stable
disease for at least 6 months on single agent VEGF inhibitor.

- Expansion Population 3: Patients with histologically confirmed glioblastoma whose
disease has failed on previous therapy, and which must have included treatment with
external beam radiation and temozolomide chemotherapy, and who now have
radiographically recurrent or progressive disease.

- Expansion Population 4: Patients with histologically confirmed advanced-stage
(unresectable or metastatic) hepatocellular carcinoma who have not received previous
systemic therapy directed at the malignant tumor will be eligible to receive
crizotinib plus sorafenib, should this combination be tested. Eligibility criteria
also include normal hepatic function or Child-Pugh hepatic function class A.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with hemorrhagic brain metastases or with known symptomatic brain metastases
requiring steroids.

- Major surgery within 4 weeks of starting study treatment.

- Radiation therapy within 2 weeks of starting study treatment.

- Hypertension that cannot be controlled with medications (>150/90 mmHg despite optimal
medical therapy).

- For glioblastoma patients: Prior treatment of glioblastoma with Gliadel wafers,
stereotactic radiation, or brachytherapy unless there is pathological or definitive
radiological evidence (PET scan or perfusion MRI) of recurrent tumor or unless there
is new enhancement outside of the radiation field. History of Grade 2 or greater acute
intracranial hemorrhage. Radiation therapy (RT) for glioblastoma within 3 months
unless there is either: a) histopathologic confirmation of recurrent tumor, or b) new
enhancement on MRI outside of the RT treatment field.Concomitant treatment with
therapeutic doses of anticoagulants (low dose warfarin (Coumadin) up to 2 mg PO daily
for deep vein thrombosis prophylaxis is allowed).

NCT01441388
Pfizer
Withdrawn
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Non-Small Cell Lung Cancer, Urothelial Cancer
NCT03472560
All Genders
18+
Years
Multiple Sites
Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC), Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03460977
All Genders
18+
Years
Multiple Sites
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
A Phase 1B, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Crizotinib (PF-02341066) Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment while the majority of patients will eventually develop evasive resistance and exhibit disease progression while on therapy. It is proposed that mesenchymal-epithelial transition factor (c-MET) and its ligand hepatocyte growth factor (HGF or scatter factor) contribute significantly to VEGF inhibitor resistance such that combining a c-MET inhibitor with a VEGF inhibitor will provide additional clinical activity compared to VEGF inhibitor alone. This hypothesis will be tested using the cMET/ALK inhibitor, crizotinib, in combination with individual VEGF inhibitors. Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Carcinoma, Renal Cell
  • Glioblastoma
  • Carcinoma, Hepatocellular
  • Drug: Crizotinib plus VEGF inhibitor combinations
    Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
  • Drug: Crizotinib plus axitinib
    Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
  • Drug: Crizotinib plus sunitinib
    Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
  • Drug: Crizotinib plus bevacizumab
    Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
  • Drug: Crizotinib plus sorafenib
    Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
  • Experimental: Dose Escalation
    Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
    Intervention: Drug: Crizotinib plus VEGF inhibitor combinations
  • Experimental: Expansion Population 1
    Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
    Interventions:
    • Drug: Crizotinib plus axitinib
    • Drug: Crizotinib plus sunitinib
  • Experimental: Expansion Population 2
    Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment.
    Interventions:
    • Drug: Crizotinib plus axitinib
    • Drug: Crizotinib plus sunitinib
  • Experimental: Expansion Population 3
    Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
    Intervention: Drug: Crizotinib plus bevacizumab
  • Experimental: Expansion Population 4
    Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested.
    Intervention: Drug: Crizotinib plus sorafenib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
November 2013
November 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Dose Escalation Population: Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available. Lesions may be measurable or non measurable.
  • Expansion Population 1: Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
  • Expansion Population 2: Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment. Resistance is defined as progression following an initial response (complete or partial), or stable disease for at least 6 months on single agent VEGF inhibitor.
  • Expansion Population 3: Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
  • Expansion Population 4: Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested. Eligibility criteria also include normal hepatic function or Child-Pugh hepatic function class A.

Exclusion Criteria:

  • Patients with hemorrhagic brain metastases or with known symptomatic brain metastases requiring steroids.
  • Major surgery within 4 weeks of starting study treatment.
  • Radiation therapy within 2 weeks of starting study treatment.
  • Hypertension that cannot be controlled with medications (>150/90 mmHg despite optimal medical therapy).
  • For glioblastoma patients: Prior treatment of glioblastoma with Gliadel wafers, stereotactic radiation, or brachytherapy unless there is pathological or definitive radiological evidence (PET scan or perfusion MRI) of recurrent tumor or unless there is new enhancement outside of the radiation field. History of Grade 2 or greater acute intracranial hemorrhage. Radiation therapy (RT) for glioblastoma within 3 months unless there is either: a) histopathologic confirmation of recurrent tumor, or b) new enhancement on MRI outside of the RT treatment field.Concomitant treatment with therapeutic doses of anticoagulants (low dose warfarin (Coumadin) up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01441388
A8081030
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now